Quest Diagnostics Earnings Call Transcripts
Fiscal Year 2026
-
Q2 2026 saw over 10% revenue growth and a 19% rise in adjusted EPS, driven by strong demand across all channels and operational improvements. Full-year guidance was raised, with robust performance in advanced diagnostics and stable financial metrics.
-
Q1 2026 saw over 9% revenue growth and a 13% rise in adjusted EPS, driven by strong organic demand, advanced diagnostics, and productivity gains from AI and automation. Full-year guidance for revenue and EPS was raised, with continued investment in innovation and digital transformation.
-
National coverage expansion and specialty test innovation drove strong volume and share gains, with advanced diagnostics and AI-enabled operations supporting growth. Major partnerships, such as the Corewell Co-Lab, and new specialty tests like Haystack MRD are expected to boost revenue and profitability.
-
Touching one-third of U.S. adults annually, the company is expanding through consumer testing, advanced diagnostics, and AI-driven efficiencies. Growth is supported by M&A, new partnerships, and a focus on prevention, with margin expansion and regulatory risks actively managed.
Fiscal Year 2025
-
Delivered double-digit revenue and EPS growth in 2025, driven by innovation, strategic partnerships, and strong demand across all channels. 2026 guidance projects 6–7.1% revenue growth, margin expansion, and continued investment in automation and advanced diagnostics.
-
Utilization and consumer demand remain strong, driving revenue and margin growth. Advanced diagnostics and partnerships are expanding, while Project Nova and Haystack MRD represent major investments with long-term productivity and innovation benefits. Policy risks like PAMA and ACA subsidies are being managed through contingency planning.
-
The symposium explored advances in multi-cancer early detection, emphasizing diverse strategies, partnerships, and the shift toward chronic disease management. Panelists highlighted the need for evidence, policy support, and integration with care systems to drive adoption and improve outcomes.
-
Q3 delivered strong revenue and margin growth, driven by robust demand, acquisitions, and consumer health momentum. Full-year guidance was raised, with continued margin expansion expected, though headwinds from PAMA and healthcare subsidies remain.
-
Consumer health and wellness partnerships are driving growth, with strong adoption and high margins. Oncology initiatives include new partnerships and MRD market entry, while Alzheimer’s blood-based testing is expanding rapidly. Structural utilization gains, M&A, and stable pricing support long-term growth.
-
A new bipartisan bill aims to reform PAMA, ensuring price stability and improved data collection, with resolution expected by year-end. Diagnostic innovation and strategic partnerships are driving double-digit growth, while major investments in technology and operations are set to streamline processes and enhance patient experience.
-
Q2 saw 15.2% revenue growth and 11.5% adjusted EPS growth, driven by strong demand, acquisitions, and advanced diagnostics. 2025 guidance was raised, with minimal expected impact from policy changes and tariffs, and robust performance across all channels.
-
Strong post-pandemic demand, innovation in diagnostics, and expansion into Canada are fueling growth. Revenue and EPS guidance remain robust, with consumer and data-driven channels accelerating. Automation, M&A, and network expansion are key strategic priorities.
-
Q1 2025 saw 12.1% revenue growth, driven by acquisitions and advanced diagnostics, with strong margin expansion and reaffirmed full-year guidance. Key developments include new enterprise partnerships, robust segment growth, and minimal tariff exposure.
-
The company projects 4-5% revenue and 7-9% EPS CAGR beyond 2025, driven by advanced diagnostics, automation, and disciplined M&A. Operational initiatives target 3% annual productivity savings, while Project Nova and AI integration will modernize systems and enhance growth.
Fiscal Year 2024
-
Q4 and full-year 2024 saw strong revenue and margin growth, driven by acquisitions, advanced diagnostics, and robust utilization. 2025 guidance projects continued organic and acquisition-driven growth, margin expansion, and significant investments in IT and regulatory compliance.
-
Pricing stability and increased transparency are supporting modest growth, while advanced diagnostics and an aging population are driving higher test volumes and revenue per requisition. Regulatory and reimbursement uncertainties persist, but ongoing M&A, automation, and innovation efforts are expected to enhance margins and market position.
-
Q3 saw 8.5% revenue growth (4.2% organic), driven by acquisitions and advanced diagnostics. Guidance for 2024 was raised, with EPS midpoint unchanged despite headwinds from Hurricane Milton and IT outages. Eight acquisitions are expected to close in 2024, supporting accelerated growth in 2025.
-
Raised 2024 guidance reflects strong organic growth, recent acquisitions, and early LifeLabs integration. Advanced diagnostics and favorable payer dynamics are driving higher revenue per requisition, while new hospital outreach deals expand market presence. Ongoing regulatory compliance, productivity initiatives, and a robust M&A pipeline support long-term growth.
-
Base business revenue grew nearly 4% and total revenue 2.5% year-over-year, driven by strong healthcare utilization, favorable test mix, and new customer wins. Four acquisitions, including LifeLabs, expand reach and advanced diagnostics. 2024 guidance raised, with margin expansion expected.